dc.contributor.author | Bilici, Ahmet | |
dc.contributor.author | Ölmez, Ömer Fatih | |
dc.contributor.author | Kaplan, Muhammed Ali | |
dc.contributor.author | Öksüzoğlu, Berna | |
dc.contributor.author | Sezer, Ahmet | |
dc.contributor.author | Karadurmuş, Nuri | |
dc.contributor.author | Çubukçu, Erdem | |
dc.contributor.author | Şendur, Mehmet Ali Nahit | |
dc.contributor.author | Aksoy, Sercan | |
dc.contributor.author | Demirci, Umut | |
dc.date.accessioned | 2024-03-13T11:10:00Z | |
dc.date.available | 2024-03-13T11:10:00Z | |
dc.date.issued | 2023 | en_US |
dc.identifier.citation | Bilici, A., Ölmez, Ö. F., Kaplan, M. A., Öksüzoğlu, B., Sezer, A., Karadurmuş, N. ... Demirci, U. (2023). Impact of adding pertuzumab to trastuzumab plus chemotherapy in neoadjuvant treatment of HER2 positive breast cancer patients: A multicenter real-life HER2PATH study. Acta Oncologica, 62(4), 381-390. https://dx.doi.org/10.1080/0284186X.2023.2202330 | en_US |
dc.identifier.issn | 0284-186X | |
dc.identifier.issn | 1651-226X | |
dc.identifier.uri | https://dx.doi.org/10.1080/0284186X.2023.2202330 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12511/12365 | |
dc.description.abstract | AimTo investigate the pathological complete response (pCR) achieved after neoadjuvant therapy with versus without adding pertuzumab (P) to trastuzumab (H) plus neoadjuvant chemotherapy (NCT) in HER2+ breast cancer (BC) patients in a real-life setting.MethodsA total of 1528 female HER2+ BC patients who received NCT plus H with or without P were included in this retrospective real-life study. Primary endpoint was pCR rate (ypT0/Tis ypN0). Clinicopathological characteristics, event-free survival (EFS) time, and relapse rates were evaluated with respect to HER2 blockade (NCT-H vs. NCT-HP) and pCR.ResultsOverall, 62.2% of patients received NCT-H and 37.8% received NCT-HP. NCT-HP was associated with a significantly higher pCR rate (66.4 vs. 56.8%, p < 0.001) and lower relapse (4.5 vs. 12.2%, p < 0.001) in comparison to NCT-H. Patients with pCR had a significantly lower relapse (5.6 vs. 14.9%, p < 0.001) and longer EFS time (mean(SE) 111.2(1.9) vs. 93.9(2.7) months, p < 0.001) compared to patients with non-pCR. Patients in the NCT-HP group were more likely to receive docetaxel (75.0 vs. 40.6%, p < 0.001), while those with pCR were more likely to receive paclitaxel (50.2 vs. 40.7%, p < 0.001) and NCT-HP (41.5 vs. 32.1%, p < 0.001). Hormone receptor status and breast conservation rates were similar in NCT-HP vs. NCT-H groups and in patients with vs. without pCR. Invasive ductal carcinoma (OR, 2.669, 95% CI 1.596 to 4.464, p < 0.001), lower histological grade of the tumor (OR, 4.052, 95% CI 2.446 to 6.713, p < 0.001 for grade 2 and OR, 3.496, 95% CI 2.020 to 6.053, p < 0.001 for grade 3), lower T stage (OR, 1.959, 95% CI 1.411 to 2.720, p < 0.001) and paclitaxel (vs. docetaxel, OR, 1.571, 95% CI 1.127 to 2.190, p = 0.008) significantly predicted the pCR.ConclusionsThis real-life study indicates that adding P to NCT-H enables higher pCR than NCT-H in HER2+ BC, while pCR was associated with lower relapse and better EFS time. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Taylor & Francis Ltd | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.subject | HER2 Protein Positive | en_US |
dc.subject | Breast Cancer | en_US |
dc.subject | Neoadjuvant Treatment | en_US |
dc.subject | Pertuzumab | en_US |
dc.subject | Trastuzumab | en_US |
dc.subject | Event-Freesurvival | en_US |
dc.subject | Relapse | en_US |
dc.subject | Real-Wordevidence | en_US |
dc.title | Impact of adding pertuzumab to trastuzumab plus chemotherapy in neoadjuvant treatment of HER2 positive breast cancer patients: A multicenter real-life HER2PATH study | en_US |
dc.type | article | en_US |
dc.relation.ispartof | Acta Oncologica | en_US |
dc.department | İstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı | en_US |
dc.authorid | 0000-0002-0443-6966 | en_US |
dc.authorid | 0000-0001-7934-7039 | en_US |
dc.identifier.volume | 62 | en_US |
dc.identifier.issue | 4 | en_US |
dc.identifier.startpage | 381 | en_US |
dc.identifier.endpage | 390 | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.identifier.doi | 10.1080/0284186X.2023.2202330 | en_US |
dc.institutionauthor | Bilici, Ahmet | |
dc.institutionauthor | Ölmez, Ömer Fatih | |
dc.identifier.wosquality | Q3 | en_US |
dc.identifier.wos | 000971681800001 | en_US |
dc.identifier.pmid | 37083566 | en_US |